{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:05:51Z","timestamp":1760234751957,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid\/lymphoid neoplasms with eosinophilia (M\/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine receptor. The correct identification of this category has relevant therapeutic implications. LIM domain only 2 (LMO2) is overexpressed in most T-LBL, but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP). Methods and Results: We retrospectively evaluated 11 cases of T-LBL occurring in the context of M\/LNs-Eo. Clinical, histological, immunohistochemical and molecular features were collected and LMO2 immunohistochemical staining was performed. The critical re-evaluation of these cases confirmed the diagnosis of T-LBL with morphological, immunohistochemical and molecular features consistent with T-LBL occurring in M\/LNs-Eo. Interestingly, LMO2 immunohistochemical analysis was negative in 9\/11 cases, whereas only 2 cases revealed a partial LMO2 expression with a moderate and low degree of intensity, respectively. Conclusions: LMO2 may represent a potentially useful marker to identify T-LBL developing in the context of M\/LNs-Eo. In this setting, T-LBL shows LMO2 immunohistochemical profile overlapping with cortical thymocytes and iT-LBP, possibly reflecting different molecular patterns involved in the pathogenesis of T-LBL arising in the setting of M\/LNs-Eo.<\/jats:p>","DOI":"10.3390\/cancers13123102","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T22:40:37Z","timestamp":1624315237000},"page":"3102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid\/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-9933","authenticated-orcid":false,"given":"Magda","family":"Zanelli","sequence":"first","affiliation":[{"name":"Pathology Unit, Azienda Unit\u00e0 Sanitaria Locale\u2014IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe G.","family":"Loscocco","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"},{"name":"Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero-Universitaria Careggi, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sabattini","sequence":"additional","affiliation":[{"name":"Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9841-7856","authenticated-orcid":false,"given":"Maurizio","family":"Zizzo","sequence":"additional","affiliation":[{"name":"Surgical Oncology Unit, Azienda Unit\u00e0 Sanitaria Locale\u2014IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"},{"name":"Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sanguedolce","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda Ospedaliero-Universitaria\u2014Ospedali Riuniti di Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Panico","sequence":"additional","affiliation":[{"name":"Pathology Unit Azienda Ospedaliera dei Colli Monaldi-Cotugno-CTO, P.O. Monaldi, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Fanni","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Medical Sciences and Public Health, University of Cagliari, 09042 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Santi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Azienda Ospedaliero Universitaria Careggi, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Caprera","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Rossi","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda USL5, 19124 La Spezia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA"},{"name":"Gastroenterology Unit, Azienda Unit\u00e0 Sanitaria Locale\u2014IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cavazza","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda Unit\u00e0 Sanitaria Locale\u2014IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Giunta","sequence":"additional","affiliation":[{"name":"Surgical Oncology Unit, Azienda Unit\u00e0 Sanitaria Locale\u2014IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mecucci","sequence":"additional","affiliation":[{"name":"Haematology Unit, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06129 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy"},{"name":"Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero-Universitaria Careggi, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-5128","authenticated-orcid":false,"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[{"name":"Haematopathology Division, European Institute of Oncology\u2014IEO IRCCS, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Ascani","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy"},{"name":"Haematology Unit, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06129 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [Revised 4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","article-title":"Myeloid\/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2","volume":"155","author":"Pozdnyakova","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/ajcp\/aqaa056","article-title":"Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia","volume":"154","author":"Mattis","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.hoc.2017.04.009","article-title":"Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis","volume":"31","author":"Gotlib","year":"2017","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","article-title":"Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","volume":"29","author":"Verstovsek","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood-2018-99-110388","article-title":"Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid\/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1)","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrc3418","article-title":"LIM-domain-only proteins in cancer","volume":"13","author":"Matthews","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2006-08-039024","article-title":"The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas","volume":"109","author":"Natkunam","year":"2006","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vazquez, I., Papaleo, N., Garcia, E., Salido, M., Salar, A., Hernandez, S., Calvo, X., and Colomo, L. (2020). Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Cancers, 12.","DOI":"10.3390\/cancers12040884"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2007.13.0690","article-title":"LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab","volume":"26","author":"Natkunam","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa032520","article-title":"Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes","volume":"350","author":"Lossos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2559.2012.04198.x","article-title":"Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody","volume":"61","author":"Agostinelli","year":"2012","journal-title":"Histopathology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ajcp\/aqv024","article-title":"LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia\/Lymphoma","volume":"145","author":"Jevremovic","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/his.14176","article-title":"LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia\/lymphoma from indolent T-lymphoblastic proliferations","volume":"77","author":"Brar","year":"2020","journal-title":"Histopathology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/j.1460-2075.1996.tb00439.x","article-title":"Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice","volume":"15","author":"Larson","year":"1996","journal-title":"EMBO J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1126\/science.1182378","article-title":"The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal","volume":"327","author":"McCormack","year":"2010","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMra032207","article-title":"Activation of the T-Cell OncogeneLMO2after Gene Therapy for X-Linked Severe Combined Immunodeficiency","volume":"350","author":"McCormack","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2006-04-019927","article-title":"The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia","volume":"108","author":"Beverloo","year":"2006","journal-title":"Blood"},{"key":"ref_21","first-page":"1434","article-title":"Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia","volume":"22","author":"Beverloo","year":"2007","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.12722","article-title":"Lymphoblastic lymphoma: An updated review on biology, diagnosis, and treatment","volume":"96","author":"Bassan","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/AJCPMF03LVSBLHPJ","article-title":"T-Lymphoblastic Leukemia\/Lymphoma","volume":"144","author":"You","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.6004\/jnccn.2020.0042","article-title":"Myeloid\/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Gerds","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106460","DOI":"10.1016\/j.leukres.2020.106460","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and FLT3 rearrangement","volume":"99","author":"Shao","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zanelli, M., Smith, M., Zizzo, M., Carloni, A., Valli, R., De Marco, L., Foroni, M., Palicelli, A., Martino, G., and Ascani, S. (2019). A tricky and rare cause of pulmonary eosinophilia: Myeloid\/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-0967-7"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1309\/AJCPMORR5Z2IKCEM","article-title":"Hematolymphoid Neoplasms Associated With Rearrangements of PDGFRA, PDGFRB, and FGFR1","volume":"144","author":"Vega","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: A review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms withFGFR1rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms withPCM1-JAK2and other rearrangements ofJAK2be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0b013e31814b226e","article-title":"t(8;13)-positive Bilineal Lymphomas","volume":"32","author":"Vega","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: A multicenter study","volume":"32","author":"Tang","year":"2018","journal-title":"Mod. Pathol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:20:32Z","timestamp":1760163632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13123102"],"URL":"https:\/\/doi.org\/10.3390\/cancers13123102","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}